Abstract
BackgroundNew evidence from clinical and fundamental researches suggests that SNHG7 is involved in the occurrence and development of carcinomas. And the increased levels of SNHG7 are associated with poor prognosis in various kinds of tumors. However, the small sample size was the limitation for the prognostic value of SNHG7 in clinical application. The aim of the present meta-analysis was to conduct a qualitative analysis to explore the prognostic value of SNHG7 in various cancers.MethodsArticles related to the SNHG7 as a prognostic biomarker for cancer patients, were comprehensive searched in several electronic databases. The enrolled articles were qualified via the preferred reporting items for systematic reviews and meta-analysis of observational studies in epidemiology checklists. Additionally, an online database based on The Cancer Genome Atlas (TCGA) was further used to validate our results.ResultsWe analyzed 2418 cancer patients that met the specified criteria. The present research indicated that an elevated SNHG7 expression level was significantly associated with unfavorable overall survival (OS) (HR = 2.45, 95% CI: 2.12–2.85, p <0.001). Subgroup analysis showed that high expression levels of SNHG7 were also significantly associated with unfavorable OS in digestive system cancer (HR = 2.31, 95% CI: 1.90–2.80, p <0.001) and non-digestive system cancer (HR = 2.67, 95% CI: 2.12–3.37, p <0.001). Additionally, increased SNHG7 expression was found to be associated with tumor stage and progression (III/IV vs. I/II: HR = 1.76, 95% CI: 1.57–1.98, p <0.001). Furthermore, elevated SNHG7 expression significantly predicted lymph node metastasis (LNM) (HR = 1.98, 95% CI: 1.74–2.26, p <0.001) and distant metastasis (DM) (HR = 2.49, 95% CI: 1.88–3.30, p <0.001) respectively. No significant heterogeneity was observed among these studies. SNHG7 was significantly upregulated in four cancers and the elevated expression of SNHG7 predicted shorter OS in four cancers, worse DFS in five malignancies and worse PFI in five carcinomas based on the validation using the GEPIA on-line analysis tool.ConclusionsThe present analysis suggests that elevated SNHG7 is significantly associated with unfavorable OS, tumor progression, LNM and DM in various carcinomas, and may be served as a promising biomarker to guide therapy for cancer patients.
Highlights
New evidence from clinical and fundamental researches suggests that small nucleolus RNA host gene 7 (SNHG7) is involved in the occurrence and development of carcinomas
Inclusion and exclusion criteria Inclusion criteria: 1) definite diagnosis or histopathology confirmed for carcinomas;2) studies investigating the prognostic values of Long noncoding RNAs (lncRNAs) SNHG7 in various cancers; 3) sufficient information for computing pooled hazard ratios (HR) and 95% confidence intervals (CI)
Subgroup analysis showed that high expression levels of SNHG7 were significantly associated with unfavorable overall survival (OS) in digestive system cancer patients (HR = 2.31, 95% CI: 1.90–2.80, p
Summary
New evidence from clinical and fundamental researches suggests that SNHG7 is involved in the occurrence and development of carcinomas. New evidence from clinical and fundamental researches suggests that lncRNA SNHG7 is expressed in many tissues and involved in the occurrence and development of various carcinomas. Due to the different nature of various cancer types, several signaling molecules associated with SNHG7 has gradually been unveiled, such as AKT2, BCL-2, BCRP, BDNF, CDK6, CTNNB1, Cyclin D1, DNMT1, E-cadherin, ELAVL1, ELK1, EMT, FAIM2, GALNT1, ID4, MDR1, Notch, p15, p16, p21, PI3K/ AKT/mTOR, PVT1, ROCK1, SMAD4, SOX4, SYVN1, TGF-β, WNT2B, Wnt/β-catenin etc [9, 10, 12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
